Title: Prevention and treatment of osteoporosis in women
Article: » print this
Summary
The British Menopause Society Council aims to aid health professionals to inform and advise women about post reproductive health. Osteoporosis affects 1 in 3 women. This guidance regarding oestrogen and non oestrogen based treatments for osteoporosis responds to the controversies about the benefits and risks of individual agents. Treatment choice should be based on up to date evidence based information and targeted to individual women’s needs.
Summary practice points
- HRT reduces the risk of both spine and hip as well as other osteoporoticfractures.
- Oestrogen remains the treatment of choice in women with premature ovarian failure
- Bisphosphonates and strontium ranelate are not advised in women with fertility aspirations
- Strontium ranelate causes a clinically significant over estimation of bone mineral density (BMD)
- Provision of adequate dietary or supplemental calcium and vitamin D is an essential part of osteoporosis management
- The effects of calcium and vitamin D supplements alone or in combinationon fracture, however, are contradictory and may depend on the study population
The full statement, scientific papers, charts, presentations etc are available in the members area. » Join here
« go back
